- Visibility 128 Views
- Downloads 97 Downloads
- Permissions
- DOI 10.18231/j.ijirm.12189.1837149538
-
CrossMark
A cross-sectional study on the impact of methylxanthines, corticosteroids, and antibiotics on COPD symptoms: Assessment using CAT, mMRC, and GOLD criteria
- Author Details:
-
Krishna Kumar Dhakchinamoorthi *
-
Kadhiravan Suseelan
-
Karthick Sivanantham
-
Gokulalakshmi Moorthy
-
Balaji Manickam
-
Sivashanmugam Muruganandham
Krishna Kumar Dhakchinamoorthi *
Background: Chronic Obstructive Pulmonary Disease (COPD) is a long-term inflammatory lung condition marked by irreversible airflow limitation. This study aimed to assess the effectiveness of a combination therapy—methylxanthines, corticosteroids, and antibiotics—on symptom relief and exacerbation frequency in hospitalized patients with COPD, using the COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) dyspnea scale.
Materials and Methods: A six-month cross-sectional observational study was conducted at Government Medical College Hospital, Tiruppur, with prior approval from the Institutional Ethics Committee. A total of 120 hospitalized patients provided informed consent and were evaluated using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification system.
Results: Among the participants, 49% were aged between 46 and 60 years. Initially, 86% had high CAT scores (21–30), which improved to a moderate range (11–20) in 90% of patients following treatment. Most patients reported mMRC grade 3 breathlessness before therapy, which improved to grade 2 afterward. In the previous year, 87% had experienced exacerbations, and 82% required hospitalization. Based on improvements in CAT and mMRC scores, the majority of patients shifted from GOLD Group C (severe) (85%) to Group B (moderate) (92%) after treatment, showing a statistically significant change (p < 0.001).
Conclusion: The combination of methylxanthines, corticosteroids, and antibiotics demonstrated greater effectiveness in alleviating symptoms and reducing disease severity in COPD patients compared to a focus on exacerbation management alone.
References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2024 Report.
- Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343(4):269–80.
- Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non- smokers. Lancet. 2009;374(9691):733–43.
- World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: WHO; 2008.
- India State-Level Disease Burden Initiative CRD Collaborators. The burden of chronic respiratory diseases in India: The Global Burden of Disease Study 2016. Lancet Glob Health. 2018;6(12):e1363–74.
- Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–54.
- Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014;44(4):873–84.
- Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–6.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease: 2023 Report. Fontana, WI: GOLD; 2023. Available from: https://goldcopd.org/2023-gold-report-2/
- Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257–
- Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–96.
- MacNee W. ABC of chronic obstructive pulmonary disease: exacerbations of COPD. BMJ. 2000;320(7234):602–6.
- Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–80.
- Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
- Cazzola M, Page CP, Rogliani P, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–
- Siddharthan T, Grigsby MR, Goodman D, Chowdhury M, Rubinstein A, Irazola V, et al. Association between household air pollution exposure and chronic obstructive pulmonary disease outcomes in 13 low- and middle-income country settings. Am J Respir Crit Care Med. 2018;197(5):611–20.
- Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.
- Lee JH, Park HY, Kim EK, Jung H, Rhee CK. Effect of inhaled therapies on spirometric outcomes in patients with COPD: A systematic review and meta-analysis. Chest. 2023;163(1):152–65.
- Yawn BP, Wollan PC, Rank MA, Bertram SL, Yawn RA. COPD treatment practices following diagnosis in primary care. Prim Care Respir J. 2016;25(2):175–81.
- Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. Am J Respir Crit Care Med. 2017;195(5):557–82.
- Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–65.
- Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–